+62.5%
DRAM vs MRNA
+436.7%
-374.2%
-44.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -5.3% | +13.1% | -18.4% | -5.6% |
| 7D | -16.6% | +20.6% | -37.3% | -17.0% |
| 30D | -26.9% | +27.1% | -54.0% | -27.2% |
| 3M | -17.8% | +353.4% | -371.2% | -22.8% |
| 6M | +6.2% | +446.3% | -440.0% | -14.1% |
| All | +62.5% | +436.7% | -374.2% | +33.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling